Publications by authors named "M Okera"
Article Synopsis
- Imlunestrant is a next-generation oral selective estrogen receptor degrader being tested in the EMBER trial for patients with ER+ advanced breast cancer and endometrioid endometrial cancer (EEC).
- The trial involves a dose-escalation design to determine optimal doses and measure safety, pharmacokinetics, and anticancer effects, focusing specifically on patients who have already undergone certain previous treatments.
- Results showed manageable side effects and some evidence of antitumor activity, with better outcomes observed when imlunestrant was combined with abemaciclib compared to imlunestrant alone.
Article Synopsis
- - Capivasertib, a selective pan-AKT inhibitor, was shown to significantly improve progression-free survival when added to fulvestrant compared to fulvestrant alone in patients with advanced breast cancer (P < 0.001), specifically those who had previously experienced disease progression on aromatase inhibitors.
- - In a randomized trial with 708 patients, individuals received either capivasertib plus fulvestrant or a placebo plus fulvestrant, with safety analyses revealing common adverse events (AEs) like diarrhea, rash, and hyperglycemia associated with capivasertib treatment.
- - Among 705 patients analyzed, 72.4% experienced diarrhea, while 38% had a rash
Article Synopsis
- CAPItello-291 is a phase 3 clinical trial studying the effects of capivasertib combined with fulvestrant on progression-free survival in patients with advanced hormone receptor-positive, HER2-negative breast cancer who experienced relapse after aromatase inhibitors.
- The trial involved a diverse group of participants, including both men and women aged 18 and older, and was conducted across 193 centers in 19 countries, focusing on those with a specific type of breast cancer and previous treatment history.
- Researchers also assessed the impact of this treatment on quality of life, symptoms, and tolerability, aiming to analyze how the new combination therapy affects overall health and wellbeing beyond just cancer progression.
Article Synopsis
- The study investigates the efficacy and safety of the AKT inhibitor capivasertib when combined with fulvestrant therapy for patients with hormone receptor-positive advanced breast cancer.
- In a phase 3 trial, patients who had previously experienced disease progression while on aromatase inhibitors were randomly assigned to receive either capivasertib with fulvestrant or a placebo with fulvestrant.
- Results showed that the combination therapy significantly improved progression-free survival: 7.2 months for the capivasertib group compared to 3.6 months for placebo, with higher rates of adverse events, such as rash and diarrhea, in the capivasertib group.
Purpose: Abemaciclib, a CDK4 & 6 inhibitor, is indicated for advanced breast cancer treatment. Diarrhea is a frequently associated adverse event of abemaciclib. The study objective was to investigate if food intake impacts local gastrointestinal toxicity.
View Article and Find Full Text PDF